CD44 and breast cancer: Furthermore, a very recent paperfrom Mylona et al. [85] indicatedthat, in clinical breast cancer tissues, the CD44+/CD24−/low phenotype (i.e., the phenotype experimentally associated with stemness) had no significantcorrelation with clinical outcome.